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Abstract
Malaria is an important treatable cause of  acute lung injury (ALI) and acute respiratory distress syn-
drome (ARDS) in the tropics and in the returning traveller in the non-endemic areas.  ARDS is an
important complication in severe, complicated falciparum malaria and has been described in P. vivax
and P. ovale malaria also.  Malarial ALI/ARDS is  more common in adults than in children. Pregnant
women and non-immune individuals are more prone to develop this condition. Increased alveolar
capillary permeability resulting in intravascular fluid loss into the lungs appears to be the key patho-
physiologic mechanism.   In malaria,  ARDS can develop either at initial presentation or after initia-
tion of treatment when the parasitaemia is falling  and the patient is improving.  Patients present with
acute onset dysnoea that can rapidly progress to respiratory failure. The diagnosis of malaria is con-
firmed by slide microscopy supported by  the use of rapid antigen tests. Patients with malarial ARDS
should be managed in an intensive care unit. Careful attention must be paid to haemodynamic
stabilisation and optimising fluid balance. Currently, specific treatment choices for malaria include
parenteral artemisinins or intravenous quinine along with doxycycline.  Respiratory failure requires
endotracheal intubation and assisted mechanical ventilation.  Co-existent bacterial sepsis is frequently
present in patients with malarial ARDS eventhough an obvious focus may not be evident. Appropri-
ate broad spectrum antibiotic therapy must be started when there is a clinical suspicion after procur-
ing the microbiological specimens. ARDS in malaria is a disease with  a high mortality. Early diag-
nosis, institution of specific antimalarial  treatment and assisted ventilation can be life-saving.
Key words Acute lung injury – acute respiratory distress syndrome – malaria – Plasmodium falciparum –  Plasmodium
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Introduction
Even today, malaria  remains a significant public
health problem globally, especially in the tropical and
subtropical areas. More than two billion people (36%
of the world population) are exposed to the risk of
contracting  malaria1,2.  Each year, malaria directly
causes nearly one million deaths and about 500 mil-
lion clinical cases,  of which 2 to 3 million  constitute
severe and complicated malaria3,4.   Recent epidemio-
logic models, geographical and demographic data
suggest that Plasmodium falciparum estimates out-
side Africa, especially in southeast Asia, are 200%
higher than reported by the World Health Organiza-
tion (WHO) — 118.94 million of global estimates of
515 million cases2,5. Malaria, like tuberculosis (TB)
has a devastating socioeconomic impact on the af-
fected countries. The term disability adjusted life
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years (DALYs) has been introduced by the WHO,
and  one lost DALY means one  lost year of “healthy
life” on account of disease (either through death or ill-
ness/disability)6,7. It has recently been estimated that
in India,  the   total DALYs lost due to malaria were
1.86 million years5.
While patients with uncomplicated malaria usually
present with fever and non-specific symptoms, severe
and complicated malaria is characterised by multi-
organ involvement including acute lung injury (ALI)
and acute respiratory distress syndrome (ARDS)8-10.
Recent years have witnessed a shift in the profile of
patients with complicated malaria5,9; multiorgan sys-
tem failure, ALI and ARDS are being increasingly
reported in falciparum malaria8,9,11,12 and in malaria
caused by the species hitherto considered benign, P.
vivax13–16, and in P. ovale17 and P. malariae18  also.
The more serious forms of malaria ravage the tropi-
cal countries where the disease is rampant. However,
increasing international travel has resulted in severe
complicated malaria and ARDS being witnessed in
industrialised countries also especially in the return-
ing travellers19–21.
Pulmonary manifestations in malaria
Pulmonary symptoms such as cough with or without
expectoration, dyspnoea, among others have been
described in patients with malaria11,12.  Historically,
three clinical  types of  pulmonary manifestations
have been variously described in patients with falci-
parum malaria, namely bronchitic, pneumonic and
bronchopneumonic forms.  It has been suggested
that malarial pneumonitis is uncommon and  these
manifestations are probably due to coincident pneu-
monia, pulmonary oedema and perhaps, metabolic
acidosis11,12.
ALI and ARDS in malaria
Our understanding of  ALI and ARDS has increased
significantly in the last two decades. Called “adult
respiratory distress syndrome” in the earlier years, the
entity is now called as “acute respiratory distress syn-
drome” as it can occur in children also. The ARDS is
a  disease with a  high mortality and is  a common
cause of admission into intensive care units  (ICUs)
all over the world22–25.
The initial reports describing  ARDS lacked specific
defining criteria.  In  1988, an expanded definition
was proposed that quantified the physiologic respi-
ratory impairment using  a four-point lung-injury
scoring system26.  Although the lung injury  scoring
system was widely employed  for research purposes
and in clinical trials, it was not found to be useful in
predicting  the outcome during the first 24 to 72 h
after the onset of the ARDS and had limited clinical
usefulness. The American-European Consensus Con-
ference definition of ALI and ARDS was published
in 199427 (Table 1). This  definition  is simple to apply
Table 1. Definitions of acute lung injury and acute
respiratory distress syndrome
Acute lung injury
Acute onset
PaO
2
/FIO
2
 < 300*
SpO
2
/FIO
2
  < 315*†
Bilateral infiltrates on the frontal chest radiograph
PCWP  < 18 mm Hg, or no clinical evidence of
    left atrial hypertension
Acute respiratory distress syndrome
Acute onset
PaO
2
/FIO
2
 <  200*
SpO
2
/FIO
2 
<  235*‡
Bilateral infiltrates on the frontal chest radiograph
PCWP  < 18 mm Hg, or no clinical evidence of left atrial
   hypertension
*Irrespective of level of positive end-expiratory pressure; †The
SpO
2
/FIO
2
  threshold of  315  yielded a sensitivity of 91% and
specificity of 56% for accurately identifying acute lung injury28;
‡The SpO
2
/FIO
2
  threshold of  235  yielded a sensitivity of  85%
and specificity of 85% for accurately identifying acute respira-
tory distress syndrome28; PaO
2
 = Arterial oxygen tension; FIO
2
=
Fraction of inspired oxygen; SpO
2 
 = Pulse oximetric measure-
ment of  oxygen saturation; PCWP = Pulmonary capillary
wedge pressure (Source: References 27, 28).
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in the clinical setting and also recognises that the se-
verity of  clinical lung injury varies  according to the
severity of arterial hypoxaemia27. Recently, pulse oxi-
metric saturation (SpO2)  to  fraction of inspired oxy-
gen (FIO2)   ratio (S/F ratio) has been found to corre-
spond to the arterial oxygen tension (PaO2) to FIO2
ratio (P/F)28.   The S/F ratio threshold value of 235 was
found to have a sensitivity of  85% and specificity of
85% for a P/F ratio  of 200 for the diagnosis of ARDS.
Similarly,  the S/F ratio threshold value of  315 was
found to have a sensitivity of  91%  and  specificity
of 56%  for a P/F ratios of 300 for the diagnosis of
ALI. These non-invasive substitutes for  assessing
oxygenation can be useful in the settings where  ar-
terial blood gas (ABG) analysis is not available and
facilitate the monitoring of the course of the disease.
Epidemiology: Reliable epidemiological data are not
available regarding the prevalence of ALI/ARDS in
patients with malaria. The prevalence of ARDS in
patients with malaria as documented in studies from
India, published in peer reviewed journals is listed in
Table 229–38. Observations from these studies and other
published reports11,12 suggest that about 5% patients with
uncomplicated falciparum malaria and  20% –30% pa-
tients with severe and complicated malaria requiring
ICU admission may develop ARDS. It should be re-
membered, however, that different denominators have
been used in various publications and meaningful
comparison of such data is not possible.  Furthermore,
in many of the previously reported studies, the precise
definition  used for the diagnosis of ARDS is also not
mentioned.
Table 2. Prevalence of ARDS in patients with malaria
Study (Reference) Denominator used  No. of patients % Prevalence of
studied  ARDS
Kochar et al  (2006)29 Patients with severe P. falciparum and mixed (P. vivax and 192* 2.1
   P. falciparum) malaria admitted to a classified malaria ward
Mishra et al (2005)30 Slide-positive patients with malaria 150† 4.6
Mohan et al (2003)9 Patients with severe falciparum malaria admitted to an 480 2.9
    ICU in a tertiary care teaching hospital
Krishnan & Karnad (2003)31 Patients with severe falciparum malaria admitted to an ICU 301 3.3
Gupta et al (2001)32 Patients admitted to a respiratory ICU 28‡ 21.4
Mehta  et al (2001)33 Patients with acute renal failure due to falciparum malaria 24 29.1
Rajput et al  (2000)34 Slide-positive patients with malaria 100§ 4
Chishti et al (2000)35 Falciparum malaria patients admitted to a district hospital 64 6.25
Murthy et al (2000)36 Falciparum malaria patients admitted to a tertiary care 158 11.4
   teaching hospital
Kochar et al  (1997)37 Patients with severe falciparum and mixed (P. vivax and 532|| 3.01
  P. falciparum) malaria admitted to a classified malaria ward
Katyal et al (1997)38 Falciparum malaria patients admitted to a medical 66 4.5
   college hospital
*Data for the year 2001; †72 (48%) were Plasmodium vivax, 54 (36%) were P. falciparum and 24 (16%) were mixed infections;
‡28 of the 120 patients who received mechanical ventilation during the study period were diagnosed to have ARDS; §53% were
P. vivax, 36% were P. falciparum, and 11% were mixed infections; ||Data for the year 1994; ARDS  = Acute  respiratory distress
syndrome.
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Pathology: The fact that  pulmonary oedema due to
malaria responds poorly to diuretics, venodilators,
and oxygen39 and the recent haemodynamic, clinical
and pathological evidence40–42 suggests that this is a
non-cardiogenic form of pulmonary oedema.
Autopsy studies39,43 in patients with severe falciparum
malaria and coma who died have revealed heavy,
oedematous lungs, congested pulmonary capillaries,
thickened alveolar septa, intra-alveolar haemorrha-
ges, hyaline membrane formation,  and serous pleu-
ral and pericardial effusions. Ultrastructural studies
corroborate the histopathological findings44,45.
Pathogenesis: The key pathogenetic events underly-
ing  the various manifestations of severe complicated
malaria include erythrocyte sequestration and de-
struction, the release of parasite and erythrocyte
material into the circulation, and the host response to
these events.  It has been suggested that malarial
parasites contain a toxin that is released at meront
rupture, which results in the genesis of fever and other
manifestations46 and  results in release and activation
of cytokines, such as tumour necrosis factor-alpha
(TNF-α) and interleukin-1 (IL-1) from macrophages
and monocytes. These cytokines are inturn postu-
lated to  induce release of other pro-inflammatory
cytokines like  interleukin-6 (IL-6) and interleukin-
8 (IL-8) and  upregulate the endothelial expression of
certain vascular ligands  that promote cytoadherence
of infected erythrocytes in the venules of vital or-
gans11,12,47.  In addition to the role played by pro- and
anti-inflammatory cytokines, neutrophil and mac-
rophage activation, a potential role for nitric oxide in
the genesis of ischaemic hypoxia has been postu-
lated12,47,48.
As in the case with ALI/ARDS due to other causes,
increased alveolar permeability is considered to be
the key functional abnormality underlying ALI/
ARDS due to malaria. However, the pathogenetic
mechanisms underlying the development of ALI/
ARDS in malaria are poorly understood. The obser-
vations such as the relatively low level of parasite
sequestration in the lungs, occasional development of
ALI/ARDS not only in P. falciparum, but also in P.
vivax or P. ovale malaria, and the occurrence of  ALI/
ARDS alone or asynchronous with  the development
of other vital organ dysfunction  suggest that some
other as yet poorly understood mechanisms may be
responsible for ALI/ARDS in malaria11,12.
Alterations in pulmonary physiology in falciparum,
vivax and ovale malaria include airflow obstruc-
tion, impaired ventilation, reduced gas transfer, and
increased pulmonary phagocytic activity49. Some
workers50 have proposed that ALI/ARDS in malaria
is likely to be a continuous spectrum from subclini-
cal lung involvement in uncomplicated malaria and
severe malaria through to frank ALI/ARDS in severe
malaria. The authors50 postulated that in patients with
severe malaria without ALI, endovascular obstruc-
tion   caused by  erythrocytes with reduced deforma-
bility, parasitised erythrocytes, and leucocytes; en-
dothelial injury and interstitial oedema result in ven-
tilation-perfusion mismatch and impairment of  gas
exchange. Furthermore, worsening or persistence of
these gas exchange   abnormalities after treatment and
beyond the expected time of clearance of parasitised
erythrocytes reflects a prolonged inflammatory re-
sponse and the genesis of ALI/ARDS50.
The tentative pathophysiological basis of ALI/ARDS
in malaria is depicted in Fig. 1. Unlike in ALI/ARDS
caused by Gram-negative sepsis, large gaps in the
knowledge exists in malarial ALI/ARDS regarding
our understanding of parasite sequestration, neutro-
phil sequestration, cytokine levels, their ratios, cau-
sation of increased alveolar  permeability,  contribu-
tion of bacterial sepsis and the cellular and molecu-
lar basis for these events. Further research is required
to understand these mechanisms.
Clinical presentation: ARDS is considered to be the
most severe form of ALI in malaria11,12. Even in the
early reports, pulmonary oedema  has been described
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Fig. 1: Pathogenetic mechanisms underlying the development of acute lung injury and acute respiratory distress syndrome in
malaria
as an important complication in patients with severe
falciparum malaria and  is frequently associated with
cerebral malaria. It has been more frequently de-
scribed in adults as compared to children.  Sometimes
ARDS may be the only manifestation of  otherwise
uncomplicated falciparum malaria39,51.
ARDS can develop at any time during the course of
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falciparum malaria, either at the time of initial presen-
tation or after following several  days of treatment,
when patients appear to be improving and when the
parasitaemia has fallen or cleared11,12,39.   Pregnant
women with severe falciparum malaria are particu-
larly prone to  develop ARDS.  In pregnant women,
the manifestations of pulmonary oedema due to
malaria can develop before, during or after labour and
is associated with a high mortality11,12.
When patients with falciparum malaria develop
ARDS, they manifest abrupt onset dyspnoea, cough,
and tightness in the chest that progresses rapidly over
a few hours to cause life-threatening hypoxia. Disori-
entation and agitation is frequently present. Physical
examination reveals signs of respiratory distress such
as air hunger, use of accessory muscles of respiration,
suprasternal and intercostal indrawing, central and
peripheral cyanosis (reflecting the severity of  arte-
rial hypoxaemia), basal crepitations and expiratory
wheezing23–26. In these patients, high parasitaemia,
acute renal failure, hypoglycemia, metabolic acido-
sis, disseminated intravascular coagulation (DIC),
and bacterial sepsis usually co-exist.
In a retrospective study, Gachot et al52 described 40
patients with complicated falciparum malaria admit-
ted to a medical ICU with (n = 12) or without (n = 28)
ALI.  Eight of the 12 patients with ALI had ARDS.
Patients with ALI  had more severe disease and had
a higher simplified acute physiology score (SAPS) on
admission (24.2 ± 3.2 vs 13.7 ± 0.7, p < 0.0001) and
a longer mean time of treatment delay (8.8 ± 2.5 vs
4.9 ± 0.6 days, p = 0.046). Acute renal failure (10/12
vs 12/28, p = 0.018), unarousable coma (8/12 vs 7/28,
p = 0.012), and metabolic acidosis (7/12 vs 4/28, p =
0.010), number of complications (4.7 ± 0.5 vs 1.6 ±
0.1, p <0.0001), septic shock (8/12 vs 2/28,
p <0.0001) were significantly more common in pa-
tients with acute lung injury. Four patients (33%)
with ALI  died compared to one (12%) without ALI
(p = 0.022). Pulmonary artery catheterisation data
obtained  from patients with ALI (n = 5) revealed
mean arterial pressure 58 ± 5 mm Hg, mean pulmo-
nary artery pressure 21 ± 2 mm Hg, mean pulmonary
artery occlusion pressure 11 ± 2 mm Hg, cardiac in-
dex 6.5 ± 0.8 l/min/m2, systemic vascular resistance
index 601 ± 100 dynes.s.cm-5/m2, and pulmonary
vascular resistance index 137 ± 77 dynes.s.cm-5/m2.
The authors52 also suggested that bacterial co-infec-
tion significantly contributed to mortality and high-
lighted the importance of  early initiation of  empiri-
cal antibiotic treatment52.
ALI and ARDS in benign malaria
Pulmonary involvement in vivax and ovale malaria
is increasingly being recognised although less fre-
quently than in falciparum malaria11,12. While some
of  these cases could be attributed to mixed infections,
published data also point out that ALI/ARDS can
develop primarily due to vivax, ovale and malariae
malaria13–18. As compared with patients with severe
complicated falciparum malaria with ALI/ARDS, the
prognosis is relatively better in ALI/ARDS in pa-
tients with benign forms of malaria.
Role of concomitant  bacterial sepsis
Bacterial sepsis is an important contributor to the gen-
esis of ALI/ARDS in severe falciparum malaria. In
patients with severe falciparum malaria, the prevalence
of bacteraemia in published studies has varied from
6%–15%11,12.  However, an obviously evident focus of
sepsis may not be discernible in many patients. Further
research is required to understand the contribution  made
by bacterial sepsis in patients with severe falciparum
malaria.  This important observation, implies that, in
endemic areas,  practicing clinicians should have a low
threshold to initiate broad spectrum antibiotics in falci-
parum malaria patients with ALI/ARDS and shock as
it can be life-saving11,12.
Diagnosis
Parasite detection: Malaria is essentially a parasito-
MOHAN et al: ALI & ARDS IN MALARIA  185
logical diagnosis. The thick (for detection of parasi-
taemia) and thin (for species identification) periph-
eral blood smear  examinations must be carried out.
Thick smear examination also facilitates quantifica-
tion of the parasitaemia. The number of parasites per
200 white blood cells can be  counted and multiplied
by the total white cell count divided by 200. Simi-
larly, in thin film, the erythrocyte parasite index can
be calculated by counting the number of parasitised
erythrocytes  per 1000  erythrocytes and multiplying
this either by the erythrocyte count or by haematocrit
multiplied by 125.611,12.
Though certain degree of correlation exists between
the severity of the disease and parasitaemia, it should
be remembered that, quantification of  the asexual
parasitaemia does not accurately reflect the parasite
load. Due to erythrocyte adherence and sequestration,
the peripheral smears may not reveal the parasite and
a negative blood smear result does not rule-out malaria.
Repeat smear examination can be rewarding  in ascer-
taining the diagnosis of malaria in severely ill patients
presenting with ALI/ARDS of obscure aetiology in
endemic areas. Various rapid diagnostic tests (RDTs)
that are available for malaria are helpful in comple-
menting good smear microscopy and should not be
considered as replacements for smear examination.
Arterial blood gas analysis: Arterial blood gas analy-
sis reveals arterial  hypoxaemia that may be refrac-
tory to oxygen therapy. Concomitant metabolic aci-
dosis may be present.
Chest radiograph: In patients with ALI/ARDS due to
malaria, chest radiographs may reveal bilateral frontal
opacities (alveolar pattern), increased interstitial mark-
ings mimicking observations in patients with ARDS due
to other causes. The cardiac size is usually normal un-
less there is co-existent severe anaemia or underlying
heart disease. Rarely, thickening of lung fissures, inter-
lobular septal lines and  pleural effusion have also been
described. In patients receiving assisted ventilation,
complications such as, pneumothorax and pneumome-
diastinum may be evident11,12.
Differential diagnosis
Malaria  must be differentiated from other acute fe-
brile conditions with dyspnoea (e.g. bacterial pneu-
monia, pleurisy), with jaundice, thrombocytopenia,
or acute renal failure (e.g., leptospirosis, sepsis syn-
drome), with confusion or coma (e.g., other causes of
meningitis, encephalitis).   In endemic areas, malaria
is an important treatable cause of ALI/ARDS  and
should be differentiated from ALI/ARDS due to other
treatable causes such as leptospirosis53, tuberculo-
sis54, enteric fever55, among others. Rarely, ALI has
been described in a patient co-infected with severe
falciparum malaria and leptospirosis56.
Management
Patients with severe complicated malaria with ALI/
ARDS should ideally be managed in an ICU because
of the high mortality associated with this condition.
General therapeutic measures: Adequate supportive
management is currently considered to be an essen-
tial component responsible for the decline in mortal-
ity observed in patients with ARDS23–26, 57. Measures
for prevention of nosocomial infections must be scru-
pulously followed. Adequate nutritional support must
be ensured preferably through the use of  enteral
nutrition as it does not cause the serious risk of cath-
eter induced sepsis. Efforts should also be directed to
prevent gastrointestinal bleeding and pulmonary
thromboembolism23–26,58. Patients with ARDS should
ideally have pulmonary and systemic arterial lines
inserted for haemodynamic monitoring and rational
fluid replacement therapy.  Monitoring arterial oxy-
gen saturation (SaO2) is preferred to PaO2  monitor-
ing because oxygen delivery is the important deter-
minant of tissue oxygenation22.
Fluid and haemodynamic stabilisation & manage-
ment: Adequate organ perfusion must be ensured in
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patients with ARDS in order to prevent abnormal
tissue oxygenation and organ failure. The intravascu-
lar volume must be maintained as low as possible
while maintaining an adequate cardiac index and
mean arterial pressure. Taking the pulmonary capil-
lary wedge pressure (PCWP) as the guideline,
adequate circulation and blood pressure is ensured
using volume  infusion (crystalloids),  vasopres-
sors23–26,58–60.
The optimal fluid management strategy in ARDS is
not yet settled with the choice ranging between a
‘conservative’ and a ‘liberal’ fluid management strat-
egies.  In a prospective randomised controlled study61,
the conservative and a liberal fluid management strat-
egies in patients with ALI were compared.   The cu-
mulative fluid balance (mean ±  SE) during the first
seven days in patients receiving the  conservative
strategy  was 136 ± 491 ml  compared to 6992 ± 502
ml  in the liberal strategy group (p < 0.001). Even-
though there was no significant difference in the pri-
mary outcome of 60-day mortality between the
conservative and liberal strategy groups (252.5 vs
28.4%; p = 0.3), the conservative strategy of fluid
management improved lung function and shortened
the duration of mechanical ventilation (number of
ventilator-free days 14.6 ± 0.5 vs 12.1 ± 0.5; p <
0.001) and intensive care without increasing non-pul-
monary-organ failures.  A similar strategy is likely to
be beneficial in ALI/ARDS  due to malaria.
A recently published randomised controlled trial62
compared the benefits and risks of haemodynamic
monitoring  guided by  a pulmonary artery catheter
with haemodynamic monitoring guided by a central
venous catheter. It was observed that pulmonary ar-
tery catheter guided therapy did not improve survival
or organ function and   was associated with more
complications than central venous catheter guided
therapy. These observations suggest that pulmonary
artery catheter should not be routinely used for  moni-
toring patients with ALI62.  In patients with severe
falciparum malaria, attempts should be directed at
maintaining the central venous pressure at 8–12 mm
Hg59. The left sided cardiac filling pressures must be
kept as low as consistent with cardiac function23–26,58,60.
Evidence is available suggesting that adrenaline ex-
acerbates lactic acidosis. Since lactic acidosis is an
independent risk factor for death in severe malaria,
the use of adrenaline is best avoided in these patients
and other vasopressors such as dopamine should be
preferred41.
Specific treatment: In patients with severe compli-
cated malaria, early institution of specific anti
malarial therapy is life-saving. In these patients par-
enteral therapy is indicated and the initiation of treat-
ment should not be delayed in patients with proven
or strongly suspected malaria. Specific antimalarial
therapy as advocated in the WHO guidelines 200663,
or the U.K. national guidelines 200764 must be used.
Two classes of drugs are currently used for the
parenteral treatment of severe complicated malaria:
the cinchona alkaloids (e.g. quinine and quinidine)
and the artemisinin derivatives (e.g. artesunate,
artemether and artemotil). The currently employed
treatment regimens are shown in Tables 3a and 3b.
In pregnant women with severe complicated falci-
parum malaria, parenteral artemisinins appear to be
a better choice  than quinine in the second and third
trimesters because quinine is associated with a higher
risk of recurrent hypoglycaemia11,12. During the first
trimester, the artemisinins or quinine may be used
and the choice should be made keeping in mind the
lower risk of quinine-induced hypoglycaemia and
the relative lack of safety data on the use of the
artemisinins11,12.
Respiratory supportive therapy: Initially, spontane-
ous ventilation using a face mask with a high flow
gas delivery system can be used to deliver a FIO2 of
up to 0.5 to 0.6. Continuous positive airway pressure
(CPAP) may be added to improve PaO2 without in-
creasing FIO2
23-26,60. If a FIO2 of more than 0.6 and
CPAP of more than 10 cm H2O are needed to achieve
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Table 3a. WHO guidelines for antimalarial treatment for severe, complicated malaria*
Artesunate  2.4 mg/kg body weight iv or im given on admission (time = 0), then at 12 and 24 h, then once a day†‡
Artemether  3.2 mg/kg body weight im given on admission then 1.6 mg/kg body weight per day‡
Quinine  20 mg salt/kg body weight on admission (iv infusion or divided im injection), then 10 mg/kg body
weight every  8 hourly; infusion rate should not exceed 5 mg salt/kg body weight per hour‡
*Severe malaria is a medical emergency. After rapid clinical assessment and confirmation of the diagnosis, full doses of
parenteral antimalarial treatment should be started without delay with whichever effective antimalarial is first
available;†Recommended choice in low transmission areas or outside malaria endemic areas; ‡Recommended for children in
high transmission areas. There is insufficient evidence to recommend any of these antimalarial medicines over another
(Source: Reference 63).
Table 3b. U.K. guidelines for antimalarial treatment for severe, complicated malaria
Quinine*† Loading dose of 20 mg/kg quinine dihydrochloride in 5% dextrose or dextrose saline over 4 h. Followed by 10
mg/kg every 8 hourly for first 48 h (or until patient can swallow).
Frequency of dosing should be reduced to 12 hourly if intravenous quinine continues for more than 48 h.
Alternative rapid quinine loading regimen (adults only) 7 mg/kg quinine dihydrochloride over 30 min  using an infusion
pump followed by 10 mg/kg over 4 h.
Doxycycline† 200 mg (or clindamycin† 450 mg three times a day for pregnant women, 7 to 13 mg/kg   three times a day
for children), given orally for total of 7 days from when the patient can swallow.
Artesunate‡§||  2.4 mg/kg given as an intravenous injection at 0, 12 and 24 h then daily thereafter.
*Parenteral quinine therapy should be continued until the patient can take oral therapy when quinine sulphate 600 mg should be
given three times a day to complete 5 to 7 days of quinine in total; †Quinine treatment should always be accompanied by a sec-
ond drug such as doxycycline or clindamycin; ‡Artesunate has not been licensed in the European Union. Treatment should never
be delayed whilst obtaining artesunate: every patient with severe malaria should be started on quinine immediately in the first
instance; §Appropriate for adults only on expert advice in certain situations where the benefits outweigh the potential disadvan-
tages of using unlicensed drug. This includes patients with parasite counts over 20%, very severe disease, deterioration on op-
timal doses of quinine, cardiovascular disease that increases the risks from quinine or patients with falciparum malaria from
southeast Asia where relative quinine resistance is likely; ||A 7-day course of doxycycline should also be given; U.K. = United
Kingdom (Source: Reference 64).
PaO2 of more than 60 mm Hg, use of non-invasive
positive pressure ventilation (NPPV) or tracheal in-
tubation and mechanical ventilation must be consid-
ered23–26,60. The aim of mechanical ventilation is to
maintain gas exchange with minimal complications.
NPPV has been tried in patients with ALI/ARDS due
to malaria13. However, NPPV requires a conscious
cooperative patient and it may not always be useful
in patients with severe complicated malaria who
present with altered sensorium or are comatose.
Though sparse published data on the appropriateness
of various ventilatory strategies in ARDS due to
malaria are available, certain generalisations can be
made basing on observations from ARDS due to
other causes.   The lung protective ventilatory strat-
egy used in the Acute Respiratory Distress Syndrome
Network (ARDSNet) study is shown in Table 465.
Sparse data are available comparing volume-con-
trolled and  pressure-controlled modes in patients
with ARDS22,25. Whether pressure-controlled or vol-
ume-controlled mode of ventilation is used, tidal
J  VECTOR  BORNE  DIS  45, SEPTEMBER 2008188
volume should be set in the region of   6 ml/kg  pre-
dicted body weight (“lung protective ventilation”)
and the  plateau pressures (end-inspiratory pause
pressures) should be limited to 30 cm H2O to prevent
lung overdistension. These have been the only meth-
ods of ventilation proven to be of value in improving
survival in patients with ARDS in randomised clini-
cal trials22,25,65–68.
Presently, peak end expiratory pressure (PEEP) is set
at a level above the lower inflection point to about 15
cm H2O in patients with ARDS.  It is also a common
practice to increase the ratio of duration of inspiration
to the duration of expiration ratio to 1:1 or 2:1 (inverse
ratio ventilation) with close monitoring of  intrinsic
PEEP (PEEPi) and haemodynamic parameters during
pressure control ventilation23–26,65–68.  There is no con-
sensus on the  optimum PEEP value. However, PEEP
and FIO2 are adjusted to arrive at the optimum PaO2.
Concern has been expressed over the issue of  permis-
sive hypercapnia because elevated arterial carbon
dioxide levels may be undesirable in comatosed
malaria patients since this can increase the cranial
blood flow and  result in  raised intracranial pres-
sure12. Further research is required to ascertain the ef-
ficacy and safety of various  mechanical ventilatory
strategies in patients with ARDS due to malaria.
Table 4. Protective lung ventilation protocol from the ARDS net study
Variable Setting
Ventilator mode Volume assist-control
Tidal volume (initial) 6 ml/kg of predicted body* weight initially. Tidal volume is
    adjusted according to plateau pressure
Plateau pressure < 30  cm H
2
O
Rate 6–35 breaths/min
Ratio of the duration of inspiration to the 1:1–1:3
    duration of expiration
Oxygenation target
PaO
2
7.3–10.7 kPa (55–80 mm Hg)
SaO
2
88–95 (%)
FIO
2
  and PEEP† FIO
2
PEEP
0.3 5
0.4 5–8
0.5 8–10
0.6 10
0.7 10–14
0.8 14
0.9 14–18
1.0 18–24
*Predicted body weight of male patients =  50 + 0.91[height (cm)–152.4], predicted body weight of  female patients  = 45.5 +
0.91 [height (cm)–152.4]; † Set according to pre-determined combinations (PEEP range 5–24 cm H
2
O); PEEP—Positive end-ex-
piratory pressure; FIO
2
—Fraction of inspired oxygen (Source: Adapted from reference 65).
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Other treatment strategies: The potential role of
corticosteroids69,70, mannitol64,71,  and exchange trans-
fusion64,72 in the treatment of severe complicated
malaria is controversial and there are no clear-cut
guidelines for their use.
Treatment of  complications of  malaria: Other com-
plications such as acute renal failure that are usually
co-existent must also be looked for and managed. In
patients with malarial acute renal failure, renal re-
placement therapy should be initiated early and neph-
rotoxic drugs should be avoided.  The indications for
dialysis support in patients with  acute renal failure
due to malaria are similar to  that for  acute renal
failure due to other causes. Haemofiltration appears
to be superior to peritoneal dialysis73.
Anaemia is an important complication of severe fal-
ciparum  malaria. If the patient is anaemic, transfu-
sion of packed erythrocytes must be considered, as
this would improve oxygenation. The WHO guide-
lines63 recommend blood transfusion when the
haematocrit falls below 20% and 15% in adults and
children respectively. While the ideal target haemo-
globin or haematocrit are difficult to generalise,
packed erythrocyte transfusion may be employed
to achieve  a target haemoglobin value of  7 to 9 g/dl
as in the case of patients with sepsis due to other
causes22.
Hypoglycaemia, a common, correctable factor that
contributes to mortality in patients with severe
falciparum malaria, especially in pregnant women.
Hypoglycaemia must be specifically looked for
by frequently monitoring blood glucose levels and
corrected.
Since bacterial sepsis is often co-existent, foci of
underlying infection should be aggressively treated
with intravenous antibiotics and surgery where
required. Wherever possible, the antibiotic choice
should be guided by the culture and sensitivity
reports.
In patients with severe falciparum malaria, thromb-
ocytopenia and activation of blood coagulation sys-
tem have been frequently described74,75. However, ac-
tivation of coagulation does not progress to frank
pathological disseminated intravascular coagulation
(DIC) in majority of the cases. Co-existent bacterial
sepsis may  also contribute  to the development of
DIC.   Presently, there is no single diagnostic test for
the definitive diagnosis of DIC.  Serial measurements
of  a  battery of  laboratory investigations,   such as
platelet count, global clotting times (activated partial
thromboplastin time and prothrombin time),  measur-
ing clotting factors and inhibitors (such as antithrom-
bin), and a test for fibrin degradation products or a
scoring system   developed by the subcommittee on
DIC of the International Society of Thrombosis and
Haemostasis76 can be used for the diagnosis of DIC.
When DIC is present, supportive treatment should be
aimed at replacement of platelets and coagulation
factors, anticoagulant treatment, and restoration of
anticoagulant pathways.  As per the recently pub-
lished International Guidelines for Management of
Severe Sepsis and Septic Shock22, platelet transfusion
is indicated when the platelet count is less than or
equal to 5000/mm3 irrespective of bleeding status.
When the platelet count is 5000/mm3  to 30000/mm3,
platelet transfusion is indicated only if there is a sig-
nificant bleeding risk.
Outcome
Definitive data on the survival in patients with
ARDS due to malaria receiving intensive care are
lacking. Available data suggest that mortality is
high in patients with ARDS due to malaria even
with  appropriate respiratory supportive therapy.
When facilities for assisted ventilation  are not avail-
able, the mortality may exceed 80% in patients with
falciparum malaria and ARDS11,12. Presence of  fal-
ciparum schizonts and/or malaria pigment in 5% or
more of  neutrophils on a blood film are considered
to be poor prognostic signs12,77,78. In a study9 of pa-
tients with falciparum malaria with acute respiratory
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failure requiring assisted ventilation  from India, in-
volvement  of two or more organ systems  (p < 0.05)
and high erythrocyte parasite index (%) (p < 0.05)
were predictors of death.
Conclusion
Malaria is an important curable cause of ALI/ARDS.
In endemic areas, or in returning travellers in non-
endemic areas, malaria should be considered as a
possible aetiological cause in patients presenting with
ARDS of  obscure aetiology.  Thick and thin periph-
eral blood smear examination usually confirms the
diagnosis; sometimes, repeat examination may be
helpful in detecting the parasite.  Early institution of
antimalarial treatment can be life-saving and initia-
tion of treatment should not be delayed in patients
with proven or strongly suspected malaria. Patients
with ALI/ARDS  are seriously ill and need to be man-
aged in an ICU setting. They require assisted me-
chanical ventilation, monitoring and correction of
anaemia, hypoglycaemia and prompt institution of
renal replacement therapy and dialysis if acute renal
failure is also present. Further research is required to
understand the pathogenetic mechanisms underlying
the genesis of ALI/ARDS and  evolve appropriate
mechanical ventilatory strategies.
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